oligonucleotide-based therapies

#JPM21: Avidity CSO Art Levin runs full speed to the clinic with 'dream' antibody oligonucleotide conjugate therapy
Endpoints
Thu, 01/14/21 - 10:34 am
Avidity
JPMHC 2021
oligonucleotide-based therapies
muscle diseases